{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:35:30Z","timestamp":1785825330248,"version":"3.56.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Australian National Health and Medical Research Council","award":["GNT1172873"],"award-info":[{"award-number":["GNT1172873"]}]},{"name":"Australian National Health and Medical Research Council","award":["GNT1172900"],"award-info":[{"award-number":["GNT1172900"]}]},{"name":"Australian National Health and Medical Research Council","award":["GNT1174555"],"award-info":[{"award-number":["GNT1174555"]}]},{"name":"NHMRC Senior Research Fellowship","award":["GNT1042907"],"award-info":[{"award-number":["GNT1042907"]}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["APP1181057"],"award-info":[{"award-number":["APP1181057"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Rising gonorrhoea rates require highly effective treatments to reduce transmission and prevent development of antimicrobial resistance. Currently the most effective treatments for pharyngeal gonorrhoea remain unclear. This review aimed to estimate treatment efficacy for pharyngeal gonorrhoea.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Online bibliographic databases were searched for the period 1 January 2000 to 17 September 2019 for treatments of gonorrhoea. All randomized controlled trials (RCTs) with data on pharyngeal gonorrhoea among participants aged 15\u2009years or above, published in English, were included. Meta-analyses (random effects) were used to estimate the treatment efficacy, defined as microbiological cure, among currently recommended monotherapies and dual therapies, previously recommended but no longer used regimens and emerging drugs under evaluation. Side effects were also summarized. The study protocol was registered on PROSPERO (CRD42020149278).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were nine studies that included 452 participants studying 19 treatment regimens. The overall treatment efficacy for pharyngeal gonorrhoea was 98.1% (95% CI: 93.8%\u2013100%; I2\u2009=\u200957.3%; P\u2009&amp;lt;\u20090.01). Efficacy was similar for single (97.1%; 95% CI: 90.8%\u2013100.0%; I2\u2009=\u200915.6%; P\u2009=\u20090.29) and dual therapies (98.0%; 95% CI: 91.4%\u2013100%; I2\u2009=\u200979.1%; P\u2009&amp;lt;\u20090.01). Regimens containing azithromycin 2\u2009g or ceftriaxone were similarly efficacious. The summary efficacy estimate for emerging drugs was 88.8% (95% CI: 76.9%\u201397.5%; I2\u2009=\u200911.2%; P\u2009=\u20090.34). Small sample sizes in each trial was a major limitation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Regimens containing ceftriaxone or azithromycin 2\u2009g, alone or as part of dual therapies are the most efficacious for pharyngeal gonorrhoea. Further pharyngeal-specific RCTs with adequate sample sizes are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa300","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T11:20:14Z","timestamp":1592652014000},"page":"3109-3119","source":"Crossref","is-referenced-by-count":30,"title":["Treatment efficacy for pharyngeal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"75","author":[{"given":"Fabian Y S","family":"Kong","sequence":"first","affiliation":[{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L","family":"Hatzis","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lau","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A","family":"Williamson","sequence":"additional","affiliation":[{"name":"Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P F","family":"Chow","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia"},{"name":"Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia"},{"name":"Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K","family":"Fairley","sequence":"additional","affiliation":[{"name":"Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia"},{"name":"Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane S","family":"Hocking","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"2020101604551118300_dkaa300-B1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2471\/BLT.18.228486","article-title":"Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016","volume":"97","author":"Rowley","year":"2019","journal-title":"Bull World Health Organ"},{"key":"2020101604551118300_dkaa300-B2","year":"2019"},{"key":"2020101604551118300_dkaa300-B3","year":"2017"},{"key":"2020101604551118300_dkaa300-B4","year":"2019"},{"key":"2020101604551118300_dkaa300-B5","first-page":"5758387","article-title":"Extragenital infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae: a review of the literature","author":"Chan","year":"2016","journal-title":"Infect Dis Obstet Gynecol"},{"key":"2020101604551118300_dkaa300-B6","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1086\/508460","article-title":"Prevalence and incidence of pharyngeal gonorrhea in a longitudinal sample of men who have sex with men: the EXPLORE Study","volume":"43","author":"Morris","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020101604551118300_dkaa300-B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00007435-199501000-00007","article-title":"Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important?","volume":"22","author":"Moran","year":"1995","journal-title":"Sex Transm Dis"},{"key":"2020101604551118300_dkaa300-B8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S1473-3099(19)30304-4","article-title":"Models of gonorrhoea transmission from the mouth and saliva","volume":"19","author":"Fairley","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2020101604551118300_dkaa300-B9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2020101604551118300_dkaa300-B10","year":"2017"},{"key":"2020101604551118300_dkaa300-B11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cmi.2019.10.015","article-title":"Is there a future for the ongoing use of azithromycin for the treatment of Neisseria gonorrhoeae?","volume":"26","author":"Kong","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2020101604551118300_dkaa300-B12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1258\/ijsa.2009.009198","article-title":"Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials","volume":"23","author":"Bai","year":"2012","journal-title":"Int J STD AIDS"},{"key":"2020101604551118300_dkaa300-B13","doi-asserted-by":"crossref","first-page":"E2182","DOI":"10.3390\/jcm8122182","article-title":"Efficacy and safety of injectable and oral antibiotics in treating gonorrhea: a systematic review and network meta-analysis","volume":"8","author":"Yang","year":"2019","journal-title":"J Clin Med"},{"key":"2020101604551118300_dkaa300-B14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/sti.2010.044586","article-title":"Azithromycin in the treatment of infection with Neisseria gonorrhoeae","volume":"86","author":"Bignell","year":"2010","journal-title":"Sex Transm Infect"},{"key":"2020101604551118300_dkaa300-B15","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2020101604551118300_dkaa300-B16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2020101604551118300_dkaa300-B17","article-title":"Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus","author":"Unemo","year":"2013"},{"key":"2020101604551118300_dkaa300-B18","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2020101604551118300_dkaa300-B19","doi-asserted-by":"crossref","first-page":"D4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"2020101604551118300_dkaa300-B20","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med"},{"key":"2020101604551118300_dkaa300-B21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1067\/mob.2001.117662","article-title":"A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy","volume":"185","author":"Ramus","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"2020101604551118300_dkaa300-B22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/OLQ.0000000000000971","article-title":"Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment","volume":"46","author":"Hook","year":"2019","journal-title":"Sex Transm Dis"},{"key":"2020101604551118300_dkaa300-B23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020101604551118300_dkaa300-B24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00007435-200103000-00003","article-title":"Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind, multicenter trial","volume":"28","author":"Stoner","year":"2001","journal-title":"Sex Transm Dis"},{"key":"2020101604551118300_dkaa300-B25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cmi.2019.08.004","article-title":"Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial","volume":"26","author":"Rob","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2020101604551118300_dkaa300-B26","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/S0140-6736(18)32817-4","article-title":"Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial","volume":"393","author":"Ross","year":"2019","journal-title":"Lancet"},{"key":"2020101604551118300_dkaa300-B27","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/cid\/ciu521","article-title":"The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea","volume":"59","author":"Kirkcaldy","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020101604551118300_dkaa300-B28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1473-3099(19)30116-1","article-title":"Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial","volume":"19","author":"Chen","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2020101604551118300_dkaa300-B29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/OLQ.0000000000000994","article-title":"Standards for treatment and control regimens in therapeutic trials for gonorrhea: lessons from a \u201cfailed\u201d trial","volume":"46","author":"Handsfield","year":"2019","journal-title":". Sex Transm Dis"},{"key":"2020101604551118300_dkaa300-B30","year":"2018"},{"key":"2020101604551118300_dkaa300-B31","first-page":"1107","article-title":"Population-level antimicrobial consumption is associated with decreased antimicrobial susceptibility in Neisseria gonorrhoeae in 24 European countries: an ecological analysis","volume":"221","author":"Kenyon","year":"2020","journal-title":"J Infect Dis"},{"key":"2020101604551118300_dkaa300-B32","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz1109","article-title":"Gentamicin alone inadequate to eradicate Neisseria gonorrhoeae from the pharynx","author":"Barbee","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020101604551118300_dkaa300-B33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00007435-199403000-00010","article-title":"Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group","volume":"21","author":"Handsfield","year":"1994","journal-title":"Sex Transm Dis"},{"key":"2020101604551118300_dkaa300-B34","year":"2018"},{"key":"2020101604551118300_dkaa300-B35","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"2020101604551118300_dkaa300-B36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0956462412472837","article-title":"2012 European guideline on the diagnosis and treatment of gonorrhoea in adults","volume":"24","author":"Bignell","year":"2013","journal-title":"Int J STD AIDS"},{"key":"2020101604551118300_dkaa300-B37","author":"Fifer","year":"2019"},{"key":"2020101604551118300_dkaa300-B38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/OLQ.0000000000000844","article-title":"A phase 1 pharmacokinetic and safety study of extended-duration, high-dose cefixime for cephalosporin-resistant Neisseria gonorrhoeae in the pharynx","volume":"45","author":"Barbee","year":"2018","journal-title":"Sex Transm Dis"},{"key":"2020101604551118300_dkaa300-B39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1258\/095646207781568556","article-title":"Pharyngeal gonorrhoea\u2013is dual therapy the way forward?","volume":"18","author":"Sathia","year":"2007","journal-title":"Int J STD AIDS"},{"key":"2020101604551118300_dkaa300-B40","year":"2016"},{"key":"2020101604551118300_dkaa300-B41","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1086\/511422","article-title":"Update on the management of gonorrhea in adults in the United States","volume":"44","author":"Newman","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020101604551118300_dkaa300-B42","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1086\/381897","article-title":"The NAAT is out of the bag","volume":"38","author":"Klausner","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020101604551118300_dkaa300-B43","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/jac\/dkz108","article-title":"Evaluation of the ResistancePlus GC (beta) assay: a commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae","volume":"74","author":"Ebeyan","year":"2019","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/11\/3109\/33893228\/dkaa300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/11\/3109\/33893228\/dkaa300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T08:56:13Z","timestamp":1602838573000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/11\/3109\/5880205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,8,3]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa300","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,8,3]]}}}